Uncategorized
GenSight Biologics becomes first gene therapy company listed in Europe
GenSight Biologics has become the first gene therapy company to be listed in Europe following an initial public offering on Euronext Paris, according to company correspondence.GenSight, founded in 2012 and based in Paris, focuses on the discovery and development of novel therapies for neurodegenerative conditions of the eye and diseases of the central nervous system.